Loss of CTLH component MAEA impairs DNA repair and replication and leads to developmental delay
- PMID: 41420108
- DOI: 10.1038/s44321-025-00352-x
Loss of CTLH component MAEA impairs DNA repair and replication and leads to developmental delay
Abstract
Ubiquitin E3 ligases play crucial roles in the DNA damage response (DDR) by modulating the turnover, localization, activation, and interactions of DDR and DNA replication proteins. We performed a CRISPR-Cas9 knockout screen focused on ubiquitin E3 ligases and related proteins with the DNA topoisomerase I inhibitor camptothecin. This led us to establish that MAEA, a core subunit of the CTLH E3 ligase complex, is a critical regulator of homologous recombination and the replication stress response. In tandem, we identified eight patients with variants in MAEA who present with a neurodevelopmental disorder that we term DIADEM (Developmental delay and Intellectual disability Associated with DEfects in MAEA). Analysis of patient-derived cell lines and mutation modeling reveal an underlying defect in HR-dependent DNA repair and replication fork restart and protection as a likely cause of disease. Mechanistically, we find that MAEA dysfunction hinders DNA repair by reducing the efficiency of RAD51 loading at sites of DNA damage, which we propose may contribute to the presentation of DIADEM by compromising genome integrity and cell division during development.
Keywords: DNA Repair; DNA Replication; Neurodevelopmental Disorder; Ubiquitin.
© 2025. The Author(s).
Conflict of interest statement
Disclosure and competing interests statement. SPJ and YG work part-time at Insmed Innovation UK Ltd. SPJ is a founding partner of Ahren Innovation Capital LLP, a co-founder of Mission Therapeutics Ltd, and is a consultant and shareholder of Genome Therapeutics Ltd. The authors declare no other competing interests.
References
-
- Akinshin A (2023) AndreyAkinshin/perfolizer
-
- Awwad SW, Serrano-Benitez A, Thomas JC, Gupta V, Jackson SP (2023) Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens. Nat Rev Mol Cell Biol 24:477–494
Grants and funding
- DRCPGM\100005/Cancer Research UK (CRUK)
- C17918/A28870/Cancer Research UK (CRUK)
- C6/A18796/Cancer Research UK (CRUK)
- C17183/A23303/Cancer Research UK (CRUK)
- C17918/A2887/Cancer Research UK (CRUK)
- SEBINT-2024/100003/cambridgeuniversity | Cancer Research UK Cambridge Institute, University of Cambridge (CRUK CI)
- C9545/A29580/cambridgeuniversity | Cancer Research UK Cambridge Institute, University of Cambridge (CRUK CI)
- 855741 (DDREAMM)/EC | ERC | HORIZON EUROPE European Research Council (ERC)
- 206388/Z/17/Z/Wellcome Trust (WT)
- 227014/Z/23/Z/Wellcome Trust (WT)
- WT203144/Wellcome Trust (WT)
- ASPIRE II Award/Mark Foundation For Cancer Research (Mark Foundation)
- Postdoctoral Career Development Award/Weizmann Institute of Science (WIS)
- Outstanding Postdoctoral Women Fellowship/Israeli Council for Higher Education
- KU 563/18-1/Deutsche Forschungsgemeinschaft (DFG)
- 393547839-SFB 1361/Deutsche Forschungsgemeinschaft (DFG)
- UKRI577/UKRI | Medical Research Council (MRC)
LinkOut - more resources
Full Text Sources
Research Materials
